← Volver a la portada
Estados Unidos · Agencias y tiempo real · PR Newswire

Frontage Announces Proposed Privatization and Asset Restructuring to Unlock Shareholder Value and Fuel Strategic Growth

Publicado por PR Newswire · Estados Unidos hace 52 min
Frontage Announces Proposed Privatization and Asset Restructuring to Unlock Shareholder Value and Fuel Strategic Growth
PR Newswire

Resumen detallado

EXTON, Pa., Nov. 16, 2026 /PRNewswire/ -- Frontage Holdings Corporation ("Frontage") (HKEX: 1521) announced a proposal by an investor consortium for (i) the privatization of…

EXTON, Pa., Nov. 16, 2026 /PRNewswire/ -- Frontage Holdings Corporation ("Frontage") (HKEX: 1521) announced a proposal by an investor consortium for (i) the privatization of Frontage from the HKEX, and (ii) a subsequent asset restructuring (together, the "Transaction"). For further details regarding the Transaction, please refer to Frontage's announcement dated November 9, 2026, available on the Frontage website: www.frontagelab.com.

As part of the asset restructuring, Frontage's business is expected to be divided among an investor consortium, comprising Charles River Laboratories, Tigermed, and Dr. Song Li, Frontage's Chairman. Specifically, upon completion of the restructuring, (i) Frontage's Exton, Pennsylvania-based bioanalysis and drug metabolism and pharmacokinetics (DMPK) business is expected to be owned and operated by Charles River Laboratories, (ii) Frontage's business in the People's Republic of China (the "PRC") and the business currently owned and operated by Acme Bioscience, Inc.

"The Transaction aims to unlock shareholder value and position Frontage for future long-term growth." Dr. Wentao Zhang and Dr. Zhongping Lin, Executive Directors and Co-CEOs of Frontage, commented, "The proposed privatization will allow management to redeploy resources directly into core operations, while the subsequent restructuring of Frontage's business will empower local business units to navigate evolving regulatory frameworks, market conditions and client dynamics with greater focus and agility."

The Transaction remains subject to shareholder and regulatory approvals, as well as customary closing conditions. Until the Transaction closes, Frontage will continue its business operations in the ordinary course. The same Frontage team will continue to support our clients on all ongoing projects, studies, and contracts with the same quality and timelines.

Further details regarding the Transaction, including the expected schedule for the shareholder meetings, will be set out in a…

W…

Inicio del artículo, extracto de PR Newswire. Para leer el resto, abra el artículo en el sitio del medio.

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

También te puede interesar